Diagnostic Testing of Iron Homeostasis and Metabolism — Coverage Criteria
This policy governs coverage for laboratory and diagnostic tests related to iron status (e.g., serum ferritin, transferrin saturation, hepcidin, GlycA) for Blue Cross Blue Shield of Tennessee members, describing indications, limitations, and which tests meet or do not meet coverage criteria.
No material clinical or coverage changes in this revision.
Coverage Criteria for Iron-Related Testing
Covered indications
Covered when ANY of the following indications are met:
See Notes referenced in policy for definitions of symptoms and first-degree relatives.
Not medically necessary / Not covered
Not covered tests:
Use of ferritin and adjunct tests to diagnose iron deficiency or overload
Covered when testing is ordered for clinical evaluation of suspected iron deficiency, iron overload, or monitoring in specific disease contexts per guideline thresholds.
References: WHO 2020; AGA guidance
Monitoring during ESA therapy
Covered when baseline and periodic iron studies are performed to guide ESA therapy in cancer-related anemia.
ASCO/ASH recommend monitoring during ESA treatment to guide iron replacement and avoid transfusions.
Indications for therapeutic phlebotomy
Covered when criteria for iron overload are met.
Therapeutic phlebotomy indicated even in non-anemic patients when clinical and laboratory criteria met.
Medically necessary indications
Covered when testing is used to evaluate or monitor iron status in the following clinical situations:
Supported by ICCAMS, KDOQI/KDIGO and related guidance.
ICCAMS and WHO/KDIGO references support these thresholds.
KDIGO/KDOQI recommendations.
ICCAMS guidance.
Iron overload / chelation monitoring
Covered with limited routine use when:
ASH guidance: serum markers useful but limited; advanced imaging required for organ risk stratification.
Neurologic iron deposition assessment
Imaging guidance for neurologic iron accumulation:
International consensus guideline for PKAN recommends MRI iron-sensitive sequences.
Contextual evidence (no explicit covered indications listed here)
No explicit coverage criteria are stated in these chunks. The section provides literature and guideline references relevant to diagnosis and management that would inform coverage decisions.
See bibliographic references listed in policy for detail.
Measurement of serum ferritin or transferrin saturation for purposes not described in the listed indications does not meet coverage criteria. Clinical requests must be supported by one of the covered indications (e.g., evaluation of abnormal hemoglobin/hematocrit, evaluation or monitoring of iron overload, symptoms of hemochromatosis, first‑degree relatives with confirmed hereditary hemochromatosis, liver disease, HLH/Still disease, male secondary hypogonadism, CKD monitoring, or individuals on iron therapy) to be eligible for coverage.
Evidence is limited for using ferritin concentrations to diagnose iron deficiency or overload in asymptomatic individuals. A recent meta-analysis found low‑certainty evidence that a threshold of 30 μg/L is reasonably sensitive and very specific for iron deficiency, and very low‑certainty evidence for ferritin to identify iron overload. Because of potential bias, indirectness, and heterogeneity in the underlying studies, ferritin alone is uncertain as a screening tool in asymptomatic populations.
The USPSTF has concluded that current evidence is insufficient to assess the balance of benefits and harms of routine screening for iron deficiency anemia in pregnancy and in children ages 6 to 24 months. These recommendations are graded as I (insufficient), indicating uncertainty about population screening and routine supplementation based on existing data.
No additional explicit exclusions are stated beyond those listed in the policy language. The referenced literature section provides supporting studies and guidelines but does not itself define additional coverage exclusions.
Certain tests are explicitly identified as not meeting coverage criteria. Serum hepcidin testing, including immunoassays, does not meet coverage criteria. Likewise, GlycA testing cannot accurately quantify individual glycoproteins such as transferrin and therefore does not meet coverage criteria for measuring or monitoring transferrin or other glycosylated proteins.
A diagnostic meta‑analysis reported overall low to very low certainty for ferritin measurement in some contexts. The authors explicitly note limited confidence in the evidence due to potential bias, indirectness, and heterogeneity across studies, supporting conservative interpretation of ferritin results when used alone.
Emerging serum markers such as non‑transferrin‑bound iron (NTBI), labile plasma iron (LPI), and other novel assays are described as interesting research tools but, owing to lack of large validation studies, are not suitable for routine monitoring and should generally be considered investigational in routine clinical practice.
Although several tests and markers are discussed in the literature citations, the policy text does not use the explicit phrase 'not medically necessary' for every marker beyond those specifically listed; however, absence of that exact wording does not alter the coverage stance documented elsewhere in the policy.
Coding and Thresholds
| No codes listed |
| 82728 | Ferritin |
| 83540 | Iron |
| 83550 | Iron binding capacity |
| 84466 | Transferrin |
| 84999 | Unlisted chemistry procedure |
| 0024U | Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative (Proprietary) |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma (Proprietary) |
| No codes listed |
Provider Actions, Authorization, and Documentation
Prior authorization for listed procedure codes
Prior authorization is not explicitly required in this policy for the listed procedure codes; however, providers should verify member-specific benefit coverage and any payer prior authorization rules at the time of service.
Using ferritin cutoffs inconsistent with guideline recommendations
Using ferritin cutoffs that are inconsistent with specialty society guidance (for example, using a ferritin cutoff of 15 ng/mL for diagnosing iron deficiency instead of the AGA-recommended 45 ng/mL in patients with anemia) may expose the claim to denial risk or request for additional documentation.
- Reference guidance: AGA recommends 45 ng/mL over 15 ng/mL when using ferritin to diagnose iron deficiency in patients with anemia.
- Clinical context: alternative cutoffs (eg, ferritin <30 ng/mL or <100 ng/mL in inflammatory states per ICCAMS) exist for different populations; document rationale if using nonstandard thresholds.
Government policy precedence
If there is any conflict between this policy and applicable government policy (for example, Medicare Local Coverage Determinations or National Coverage Determinations, or state Medicaid rules), the relevant government policy takes precedence.
No explicit denial triggers present in the policy
The policy does not define explicit denial triggers; absence of a stated trigger does not preclude denial where member benefits, lack of medical necessity, or noncompliance with applicable regulations apply. Providers should supply supportive documentation when clinical indications are borderline or nonstandard.
- No specific procedural denial conditions are listed in this document.
- Claims may still be denied for insufficient medical necessity or if member benefits exclude the service.
No explicit authorization or denial criteria beyond coverage statements
This policy does not provide an explicit set of authorization or denial criteria beyond the coverage indications and limitations; clinical coverage decisions should be supported by the documented indications in Section II and applicable references.
- Coverage is supported when measuring ferritin or transferrin saturation for specified indications (eg, evaluation of abnormal hemoglobin/hematocrit, suspected hemochromatosis, monitoring CKD patients on ESA therapy).
- For scenarios not listed, ferritin or transferrin testing does not meet coverage criteria per Section II.
Required diagnostic documentation
Required diagnostic documentation to support testing should include clinical indication, relevant signs/symptoms or family history, and supporting laboratory values. For monitoring during therapy, document treatment context and frequency.
- Document reason for test (eg, abnormal hemoglobin/hematocrit, symptoms of hemochromatosis, first-degree relative with HH, monitoring CKD/ESA therapy).
- Include recent CBC, prior iron studies (ferritin, TSAT), and any imaging or specialist notes if applicable.
- For ESA therapy: document baseline and periodic iron indices and rationale for iron replacement per ASCO/ASH and KDIGO guidance.
No explicit documentation requirements specified
The policy contains no additional, specific documentation requirements (eg, forms or templates) beyond clinical and laboratory information; providers should retain source documents that justify medical necessity and align with specialty guidance.
- No policy-specified documentation templates or assay-method validation details are required.
- If using nonstandard tests (eg, GlycA, hepcidin), note that GlycA and hepcidin testing are listed as not meeting coverage criteria.
Iron replacement with ESA therapy
Iron replacement in the setting of ESA therapy is recognized in specialty guidance: iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESAs. Document baseline and periodic iron indices when treating with ESAs per ASCO/ASH and KDIGO recommendations.
- Monitor TSAT and ferritin at least every 3 months during ESA therapy; test more frequently when initiating/increasing ESA dose or after blood loss or IV iron.
- Document indication for iron replacement and response to therapy.
Background on Iron Metabolism and Testing
Iron homeostasis is tightly regulated. Dietary iron is absorbed by enterocytes via divalent metal transporter‑1 (DMT1) or heme endocytosis, exported through ferroportin, and bound to transferrin for delivery to erythroid precursors. Intracellular iron is stored in ferritin, and systemic iron export is controlled by the peptide hormone hepcidin, which induces ferroportin degradation. Ferritin is also an acute‑phase reactant and may be elevated in inflammation, liver disease, or malignancy independent of iron stores.
Definitions and Biomarker Descriptions
Biomarker Requirements and Characteristics
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.